Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
malaria vaccine (Advax adjuvanted)
- Development stage
- Preclinical
- Lead developer
- Vaxine
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The malaria vaccine (Advax adjuvanted) is a recombinant protein subunit vaccine candidate developed by Vaxine. It is designed to elicit protective antibody and T-cell responses against Plasmodium antigens to prevent malaria infection and disease. The vaccine utilizes Vaxine's proprietary Advax adjuvant, which is based on delta-inulin, a unique polysaccharide that enhances immune responses without the inflammatory side effects often associated with traditional adjuvants. Currently in preclinical development, the vaccine aims to provide a robust and durable immune response against malaria parasites.
- Other names
- Advax adjuvanted malaria vaccine
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on malaria vaccine (Advax adjuvanted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on malaria vaccine (Advax adjuvanted).